The Research Roadblock: Why CBD and Cannabis Studies Face Unprecedented Barriers in the U.S.

From 1999 to 2018, the pharmaceutical industry spent $4.7 billion on federal lobbying—more than any other industry—and contributed an additional $1.3 billion to political campaigns. During this same period, cannabis remained locked in Schedule I classification, the most restrictive drug category, making it nearly impossible for researchers to conduct the clinical trials needed to validate therapeutic claims about CBD and other cannabinoids.

The timing isn’t coincidental. While pharmaceutical companies were building extensive cannabis patent portfolios—with Canada’s top 10 cannabis patent holders including Pfizer, Ciba-Geigy, and Merck—independent academic researchers faced regulatory mazes that delayed studies for years and often made research financially impossible.

The December 2024 Trump administration order reclassifying cannabis to Schedule III and establishing a Medicare CBD pilot program has thrown these dynamics into sharp relief. The move promises to unlock research—but also positions major pharmaceutical companies to dominate a market they spent decades keeping others out of.

This investigation examines the structural barriers that have stymied CBD and cannabis research in the United States, the industry influences shaping policy, and what the recent regulatory shift means for the future of cannabinoid medicine.

The Research Stranglehold: How Schedule I Classification Blocked Science

Schedule I status created interconnected barriers where overcoming one obstacle required success in surmounting others—a regulatory catch-22 that effectively froze cannabis research for decades.

The Single-Source Problem

Until recently, researchers could only obtain cannabis from a single DEA-registered source: the University of Mississippi, under contract with the National Institute on Drug Abuse. This monopoly created severe limitations.

The cannabis provided often contained much lower THC levels than products available in state dispensaries. The highest THC content in research cigarettes was 6%, compared to 20-30% in commercial products. When experienced cannabis users were asked to smoke 8% THC cigarettes in trials, they couldn’t finish them—forcing researchers to use concentrations that didn’t reflect real-world use.

More problematic, the drying process destroyed terpenes, the aromatic compounds that may enhance cannabinoid effects through the entourage effect. Researchers trying to study whole-plant medicine were forced to work with degraded material missing key components.

The Three-Agency Gauntlet

Conducting cannabis research requires approval from the DEA (Schedule I registration), obtaining cannabis from NIDA or another DEA-registered source, and FDA review of research protocols. Each agency operates independently with different timelines and requirements.

A researcher at University of California Davis attempting to study cannabis faces additional hurdles: approval from the California Attorney General’s Research Advisory Panel, institutional review boards, strict security requirements, and restrictions on funding sources. UC researchers cannot accept funding from entities that derive most revenue from the cannabis industry, eliminating many potential research sponsors.

These barriers don’t just delay research—they make it prohibitively expensive for most academic institutions and effectively impossible for small research teams without substantial institutional backing.

The Funding Desert

Until recently, very few funding opportunities existed for research on therapeutic effects of cannabis and cannabinoids. While the NIH cannabis research portfolio has grown, it remains dwarfed by funding for other medical conditions affecting similar numbers of patients.

In 2019, the NIH budget for research projects was approximately $9.6 billion, with an overall funding rate of 19%. Cannabis research competes within this limited pool while carrying additional regulatory burdens that increase costs and timelines.

Dr. Donald Abrams’ research team experienced this firsthand. When designing a study on sickle cell pain, they envisioned a four-arm trial comparing THC-dominant cannabis, CBD-dominant cannabis, a balanced blend, and placebo. Funding limitations forced them to cut the study to two arms—one active treatment and one placebo—eliminating their ability to compare different cannabinoid profiles.

The Pharmaceutical Industry’s Dual Strategy

While academic researchers struggled with regulatory barriers, pharmaceutical companies pursued a different path: building patent portfolios and waiting for federal policy to shift in their favor.

The Patent Land Grab

Data shows U.S. cannabis patent holders nearly tripled in three years. Patent holders include pharmaceutical giants, three U.S. universities, the U.S. Department of Health and Human Services, and the National Institutes of Health.

In Canada, seven of the top 10 cannabis patent holders are major multinational pharmaceutical companies: Ciba-Geigy AG (21 patents), Pfizer Products (14 patents), Telefonaktiebolaget LM Ericsson (13 patents), and Merck Sharp and Dohme Corporation (11 patents).

The irony runs deep. Major pharmaceutical companies were making and selling medical cannabis products in the early 1900s, including Squibb, Parke Davis, Eli Lilly, Merck, and Johnson & Johnson. About 6% of all pre-1937 medicines contained cannabis. These same companies supported prohibition policies that locked cannabis in Schedule I for decades while they secured patents for future commercialization.

The Lobbying Machine

The pharmaceutical industry maintains unmatched political influence. In 2022 alone, pharmaceutical and health product companies spent over $372 million on federal lobbying—more than any other industry. There are currently more than three pharmaceutical lobbyists for each member of Congress, with over half being “revolving door” hires who previously served in government.

PhRMA, the pharmaceutical industry’s primary trade group, spent $29.2 million on lobbying in 2022 alone. The organization has historically worked to shape policies affecting drug development, approval processes, and market access.

Research shows that lobbying in the pharmaceutical industry can speed FDA approval and increase the scope of new drugs. A formal analysis found that pharmaceutical companies strategically allocate resources between R&D and lobbying to maximize drug development outcomes and regulatory favorable treatment.

The Research Funding Conflict

Academic researchers who receive cannabis industry funding face ethical scrutiny similar to tobacco research. Yet pharmaceutical companies funding research on synthetic cannabinoids face minimal criticism.

Universities accepting multi-million-dollar donations from cannabis companies—such as University of British Columbia’s CA$2.5 million from Canopy Growth—triggered ethics concerns about biased research. Meanwhile, pharmaceutical companies have funded decades of research on synthetic THC products like Marinol and Syndros without similar scrutiny.

Industry-funded research consistently shows bias toward sponsor products. A review of over 600 studies since 2018 found industry-sponsored research significantly more likely to yield favorable results for sponsor products than independently funded studies. This creates an environment where pharmaceutical companies can fund research supporting their synthetic cannabinoids while plant-based cannabis research remains underfunded and restricted.

The Regulatory Maze: Designed to Favor Synthetic Over Plant-Based

The classification system for cannabinoids reveals regulatory logic that seems designed to advantage pharmaceutical companies over plant-based medicine.

The Synthetic vs. Plant Paradox

According to DEA rules following the 2018 Farm Bill, CBD derived from hemp plants with less than 0.3% THC is decontrolled and legal. Yet synthetic CBD—chemically identical—remains Schedule I under the Controlled Substances Act. The molecule is the same, but its origin determines regulatory standing.

The classification of delta-9-THC is even more Byzantine. Dronabinol (synthetic delta-9-THC) exists on three different schedules depending on formulation: oral capsules (Marinol) are Schedule III, FDA-approved liquid (Syndros) is Schedule II, and dronabinol not packaged according to FDA formulations is Schedule I.

This regulatory framework gives pharmaceutical companies clear advantages. They can develop synthetic cannabinoids, navigate the FDA approval process they’re already expert in, and bring products to market under less restrictive scheduling than plant-based alternatives.

The Approval Pathway Disparity

Pharmaceutical companies are accustomed to competing in IP-protected environments with patent exclusivity until loss of protection. Phytocannabinoids like THC and CBD are known molecules, presenting commercialization challenges for branded pharmaceutical companies.

The solution? Develop synthetic versions, novel formulations, or new cannabinoid combinations that qualify for patent protection. GW Pharmaceuticals’ Epidiolex, a purified CBD extract approved for rare epilepsies, demonstrates this path: take a known plant compound, put it through FDA trials, and secure market exclusivity despite CBD’s availability in countless over-the-counter products.

The FDA approval process itself favors large pharmaceutical companies. Bringing a drug through Phase I-III clinical trials to FDA approval requires hundreds of millions of dollars and expertise in navigating regulatory requirements. Few cannabis companies possess these resources. Pharmaceutical companies do.

The December 2024 Shift: Opening Research or Opening Markets?

Trump’s executive order reclassifying cannabis to Schedule III and launching a Medicare CBD pilot program represents the most significant federal cannabis policy change in decades. The implications extend far beyond patient access.

What Schedule III Means for Research

Trump stated that reclassification “leads to tremendous amounts of research that can’t be done unless you reclassify”. Schedule III status removes some research barriers:

• Eliminates need for special DEA Schedule I registration
• Potentially allows multiple cultivation sources beyond University of Mississippi
• May streamline institutional approval processes
• Could increase federal research funding opportunities

However, regulatory frameworks remain under development, and substantial oversight requirements will likely persist. Researchers still face FDA protocol reviews, state-level regulations, and institutional restrictions.

The Medicare CBD Pilot: Embedding Cannabis in Healthcare

The Medicare pilot program will provide certain seniors with free, doctor-recommended CBD products starting in April 2025. Products must comply with local and state laws, come from legally compliant sources, and undergo third-party testing.

Critics warn the proposal is outpacing the science. Studies have found “inconsistent benefits” for targeted conditions, and FDA-funded research warns prolonged CBD use can cause liver toxicity and interact with lifesaving medications.

The move could embed cannabis-derived products into the U.S. healthcare system despite limited clinical evidence. Medicare coverage typically signals insurance reimbursement and triggers institutional investment—potentially from the pharmaceutical companies that spent decades blocking research.

Wall Street’s Interpretation

Cannabis company stocks dropped following the announcement. Trulieve fell 23%, Green Thumb Industries dropped 16%, and the AdvisorShares Pure US Cannabis ETF slid 27%.

Investors understood the implications: rescheduling and Medicare coverage will likely trigger new investments from institutional capital that typically follows federal insurance coverage to big pharmaceutical companies. Large pharmaceutical companies have the deep pockets needed to fund multiyear, double-blind clinical trials required for FDA-approved drugs—a barrier few current cannabis operators can surmount.

Timothy Seymour, founder of Seymour Asset Management, noted: “The pharma sector, in the past, has been a major lobbyist against [cannabis] because it is a threat.” With rescheduling removing their primary objection, pharmaceutical companies can now enter the market they helped restrict.

The “Spin” Phenomenon: When Positive Results Get Negative Conclusions

Beyond regulatory barriers and funding biases lies a more insidious pattern: research showing cannabinoid benefits often concludes with recommendations against their use. This phenomenon, known as “spin bias” in medical literature, appears with striking frequency in cannabis research.

What Is Spin Bias?

Spin refers to distorted interpretation of research results that unjustifiably suggests favorable or unfavorable findings, creating misleading conclusions. Research across medical fields shows spin is pervasive—68% of abstracts in a wide sample contained some form of spin, with the most severe types involving recommendations inconsistent with actual study findings.

The problem is particularly acute in abstracts, where clinicians often make decisions without reading full studies. In one analysis of wound care trials, 74% of main texts included statistically nonsignificant outcomes, but only 28% of abstracts mentioned these negative results. The abstract conclusions cherry-picked positive secondary findings while burying the failed primary outcomes.

Spin Patterns in Cannabis Research

Cannabis research exhibits specific spin patterns that minimize positive findings:

Emphasizing limitations over results: Studies finding CBD benefits often devote disproportionate space to methodological limitations while downplaying positive outcomes. Conclusions state “more research is needed” despite demonstrating clear effects.

The “approaching significance” dismissal: When CBD shows benefits at p=0.06 or p=0.08—just above the arbitrary 0.05 threshold—researchers dismiss findings as “not statistically significant” rather than acknowledging meaningful clinical effects. This represents interpretation bias where authors downplay results that don’t fit expectations.

Subgroup analysis suppression: Positive findings in subgroups get buried while negative overall results dominate conclusions. For example, if CBD helps male patients significantly but shows mixed results in females, conclusions emphasize “no overall effect” rather than noting the strong male response.

Secondary outcome minimization: When primary outcomes show modest benefits but secondary measures demonstrate strong effects, conclusions focus on the “failed” primary endpoint. This selective emphasis distorts the overall picture of therapeutic potential.

A Documented Example Pattern

A comprehensive pharmacology-based systematic review examined 152 randomized controlled trials of medical cannabinoids including CBD. The meta-analysis found:

• Moderate evidence for therapeutic effects on chronic pain, spasticity, sleep, and substance use disorders
• Low to very low evidence for other conditions primarily due to missing trials and small sample sizes
• The conclusion stated cannabinoids are “effective therapeutics for several medical indications if their specific pharmacological properties are considered”

Yet the abstract emphasized evidence quality limitations more prominently than actual therapeutic benefits documented. This represents a classic example where methodology concerns overshadow positive clinical findings.

The Funding Connection to Spin

Studies with industry funding show significantly different spin patterns than those funded by pharmaceutical companies. Analysis of CBD research found:

• 79.6% of studies with CBD-industry funding had supportive results
• 61.6% of human studies included CBD-related conflicts of interest
• Nearly 80% of CBD-industry-funded studies showed positive results compared to 62.2% of independent studies

But here’s the critical pattern: pharmaceutical-funded research on synthetic cannabinoids receives minimal scrutiny for funding bias, while CBD research faces heightened skepticism regardless of methodology quality.

The “More Research Needed” Trap

Cannabis researchers face a catch-22: regulatory barriers make large-scale trials nearly impossible, then the lack of large-scale trials justifies dismissing positive findings from smaller studies as “requiring confirmation.”

Analysis of federal cannabis research funding reveals the three largest funders—NIDA, NIAAA, and NIMH—focus primarily on adverse effects rather than therapeutic potential. From 2000-2018, NIDA prioritized research on cannabis abuse, negative health effects, and social impacts while providing minimal support for therapeutic research.

This creates a systematic bias where negative findings receive ample funding and publication support, while positive therapeutic findings face higher evidentiary bars and more critical peer review.

Reverse Spin: The Negative Result Paradox

Research with negative findings about CBD or cannabis receives less scrutiny and easier publication in high-impact journals. Studies showing “no benefit” rarely face demands for replication or criticism of methodology, while positive findings trigger intense scrutiny.

A well-designed study on hip osteoarthritis treatment found the intervention no better than placebo. Researchers reported difficulty publishing in targeted journals despite rigorous methodology—until the findings aligned with expectations, they weren’t considered “interesting” enough.

The opposite pattern appears with cannabis research. The 2023 Lancet study showing CBD didn’t help knee osteoarthritis received widespread coverage and minimal methodological criticism. Yet the study used a dose (150mg daily) that may have been insufficient given CBD’s poor oral bioavailability—a limitation barely mentioned in the abstract.

Publication Bias Against Positive Results

Cannabis research exists at the intersection of healthcare, commerce, and policy, creating unique publication pressures. The “file-drawer problem”—where negative results remain unpublished—operates in reverse for cannabis.

Positive cannabis findings face additional hurdles:

• Reviewers demand higher standards of evidence
• Journal editors may reject positive results as “not interesting enough” given prohibition’s legacy
• Researchers may self-censor positive findings to avoid career damage from association with a stigmatized substance

Systematic reviews show non-Cochrane reviews are twice as likely to have positive conclusions than Cochrane reviews—but cannabis research shows the opposite pattern, where even supportive findings get hedged with excessive caution.

The Language Evolution

Analysis of PubMed abstracts from 1974-2014 found increasing use of positive language in scientific writing—except in stigmatized research areas. Cannabis research language has grown more cautious over time rather than more confident, despite accumulating evidence.

Researchers use phrases like “may suggest possible benefits” when pharmaceutical research would state “demonstrated significant improvements.” This linguistic hedging, combined with disproportionate emphasis on limitations, creates abstracts and conclusions that understate therapeutic potential.

Impact on Clinical Practice

Experiments show readers of studies with spin draw more favorable interpretations than when results are presented objectively. When cannabis research contains inverse spin—minimizing positive findings—clinicians form unfairly negative impressions.

This influences press releases and media coverage, with journalists echoing cautious abstracts rather than examining full data. Studies obtaining press coverage receive more citations, amplifying the impact of spin on medical consensus.

Breaking the Pattern

The registered reports model offers one solution: journals commit to publishing studies based on methodology before results are known. This reduces incentive to spin findings since publication is guaranteed regardless of outcome direction.

Enhanced transparency requirements help too. Requiring data availability statements and systematic comparison of abstracts against full results can expose discrepancies where conclusions don’t match data.

Most importantly, readers must develop critical appraisal skills to identify spin. When conclusions emphasize “more research needed” despite clear positive findings, or when abstracts focus exclusively on limitations while burying benefits in the full text, spin is likely present.

The Path Forward: What Needs to Change

The regulatory landscape is shifting, but fundamental problems remain unaddressed.

Independent Research Funding

Current NIH cannabis research funding pales compared to other medical conditions affecting similar patient populations. Dedicated federal funding for independent cannabis research—free from pharmaceutical industry influence—is essential for unbiased science.

Transparent Industry Influence Tracking

The theory of dependence corruption explains how the pharmaceutical industry deflects broader public interests. Academic research must uncover how drug firms shape policy frameworks, subsidize political allies, and influence congressional voting.

Public databases tracking pharmaceutical lobbying, campaign contributions, and regulatory outcomes would enable researchers and journalists to identify patterns of industry influence on cannabis policy.

Eliminating Funding Source Restrictions

Universities cannot accept cannabis industry research funding while freely accepting pharmaceutical company funding. This double standard handicaps cannabis research while giving pharmaceutical companies uncontested influence over cannabinoid science.

Conflict-of-interest disclosures should apply equally regardless of whether funding comes from cannabis companies or pharmaceutical corporations.

Expanding Cultivation Sources

The 2020 DEA rule intended to allow more cultivation sources, but the cannabis research community found it too restrictive. Researchers need access to cannabis products that reflect what consumers actually use—including high-THC strains, products with intact terpene profiles, and formulations beyond dried flower.

Addressing the Patent Problem

Pharmaceutical companies have built extensive cannabis patent portfolios while research remained restricted. These patents may block or limit development of plant-based cannabis medicines, forcing consumers toward more expensive pharmaceutical alternatives.

Patent reform ensuring that known plant compounds remain accessible for medical use would prevent pharmaceutical companies from monopolizing cannabinoid medicine.

The Bottom Line

The structural barriers facing cannabis and CBD research in the United States aren’t accidental. They emerge from a regulatory framework shaped by decades of pharmaceutical industry lobbying, strategic patent accumulation, and policies that favor synthetic compounds over plant-based medicine.

The pharmaceutical industry spent $4.7 billion on federal lobbying from 1999-2018—more than any other industry—while cannabis remained locked in Schedule I. Major pharmaceutical companies secured hundreds of cannabis patents while independent researchers struggled to obtain plant material for basic studies.

The December 2024 rescheduling represents progress, but it also positions pharmaceutical companies to dominate a market they spent decades keeping restricted. Medicare coverage could attract major pharmaceutical players seeking federally insured revenue, potentially displacing smaller cannabis companies and limiting consumer choices.

True reform requires more than rescheduling. It demands independent research funding, elimination of cultivation monopolies, transparent tracking of industry influence, and policies ensuring plant-based cannabis medicine remains accessible alongside pharmaceutical alternatives.

The science of cannabis therapeutics has been delayed by decades. Whether the current regulatory shift accelerates research or simply transfers control from Schedule I restrictions to pharmaceutical company patents remains to be seen. What’s certain is that patients deserve access to the full spectrum of cannabinoid medicine—not just the synthetic versions pharmaceutical companies find profitable to patent.